TMCnet News
Poxel Announces Upcoming Presentations on New Imeglimin Data at Two Key Scientific ConferencesPOXEL (Euronext - POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, announced today that the Company will present new data for its lead program, Imeglimin, at two respected scientific forums in Europe and the US. Specifically, the Company will present at the 6th World Congress on Targeting Mitochondria in Berlin, Germany, October 28-30, 2015. In addition, the Company has had an abstract accepted for poster presentation at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease Congress (WCIR) in Los Angeles, California, November 19-21, 2015.
Targeting Mitochondria Congress
World Congress on Insulin Resistance and Cardiovascular Diseases Poxel will announce the results through a press release at the time of the data presentations. About Poxel Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20151006006815/en/ |